Ablynx is granted extended GMP certificate
Advertisement
Ablynx announced that it has been granted an extended Certificate of Good Manufacturing Practice (GMP) from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium for its new GMP unit at its headquarters in Ghent, after having been inspected in November 2011.
Having received this accreditation, Ablynx's GMP unit will now perform release-testing on Drug Substance and Drug Product batches and independently perform all stability studies on these batches. The large scale GMP manufacturing of Nanobodies® will continue to be outsourced to contract manufacturing organisations (CMO).
Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "GMP certification of our laboratories in Ghent is a testament to Ablynx's commitment to consistently perform at a high standard in our internal and partnered development programmes. This is an important step forward as we continue to transform into a product-based company."
Other news from the department politics & laws
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Cells as computers - Such reprogrammed cells could perform medical tasks in our bodies, such as diagnosing diseases or providing treatment
17 Million for Future Cancer Diagnoses
BioVaria Startup Awards go to OPSYON and LIfT Biosciences - 11th BioVaria Sees Record Attendance
Phylogica licenses technology to Janssen Biotech, Inc.
Biotools, B & M Labs, S.A. - Madrid, Spain
Structure of key complex in the immune system - New study reveals the structure of complement component C1 – a target for complement-mediated diseases including strokes and heart attacks
Computer tool analyzes in detail genetic alterations in the genome of cancer cells - Developed by CSIC, CiberAMP allows establishing direct correlations between changes in the number of gene copies in tumor cells and their expression levels
Proteros and CHDI Foundation, Inc. establish discovery services collaboration to address Huntington’s disease
Horizon Discovery Group plc, Centre for Process Innovation and University of Manchester Awarded £1.67M - Consortium to receive funding to develop enhanced biomanufacturing platforms based on the Company’s CHO cell line and gene editing platform